Companies:

 

Articles:

 

Stock summary

Companies:

 

Paradigm Biopharmaceuticals Limited.. (ASX: PAR)

 
Service provided by WebLinkIR

Company news

Cover Image for Paradigm’s iPPS shown to reduce cartilage loss and improve function in osteoarthritis patients

Paradigm’s iPPS shown to reduce cartilage loss and improve function in osteoarthritis patients

Cover Image for Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise

Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise

Cover Image for Paradigm Biopharmaceuticals advances Zilosul osteoarthritis program, to trial drug in MPS patients

Paradigm Biopharmaceuticals advances Zilosul osteoarthritis program, to trial drug in MPS patients

Cover Image for Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact

Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact